MYL3抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P08535(MYL3 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08535(MYL3 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08535(MYL3 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The MYL3 antibody targets myosin light chain 3 (MYL3), a protein encoded by the MYL3 gene, which is part of the regulatory light chain family involved in muscle contraction. MYL3. also known as ventricular myosin essential light chain, is predominantly expressed in cardiac and slow skeletal muscle tissues. It binds to the myosin heavy chain, forming part of the myosin complex critical for ATPase activity and force generation during muscle contraction. MYL3 plays a key role in stabilizing the myosin lever arm, influencing contractile efficiency and calcium sensitivity.

Research using MYL3 antibodies focuses on understanding cardiac pathophysiology, particularly hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), as MYL3 mutations are linked to these disorders. These antibodies are employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect MYL3 expression levels, localization, and interactions in tissue samples or cell models. Studies also utilize MYL3 antibodies to explore structural and functional changes in MYL3-deficient or mutated models, providing insights into disease mechanisms. Additionally, they aid in differentiating MYL3 isoforms from other myosin light chains (e.g., MYL2) in experimental analyses. Their application contributes to advancing diagnostics and therapeutic strategies for muscle-related diseases.